BiomX Inc. announced that it is discontinuing its Phase 2b nebulized phage therapy trial (BX004) for cystic fibrosis patients. The decision follows an internal analysis and a Data Monitoring Committee (DMC) review that identified unexpectedly high rates of adverse events, including severe respiratory irritation and transient bronchospasm in a subset of participants. The DMC had recommended continuing the trial with an adjusted dosing strategy on November 25, but the company concluded that the timelines and resources required to implement that strategy exceeded its available capacity.
Continue reading for full analysis...
BiomX Inc. (PHGE) announced a 1‑for‑19 reverse stock split of its common shares, effective at the opening of the market on November 25, 2025. The action will reduce the number of outstanding shares from roughly 29 million to about 1.5 million and will change the company’s CUSIP to 09090D 509. All equity awards, warrants and convertible preferred stock will be adjusted proportionally, while the par value and authorized share count remain unchanged.
Continue reading for full analysis...
BiomX Inc. reported its Q3 2025 earnings on November 12, 2025, posting a net loss of $9.2 million, a reversal of the $9.6 million net income recorded in the same quarter of 2024. The loss was driven largely by a decline in the fair value of warrants, which offset gains in operating performance.
Continue reading for full analysis...